Targeted and Immunotherapies
Read about cancer treatment options listed by gene mutation, type of cancer and type of treatment.Stay up to date on research and information
Sign Up for FORCE NewslettersTargeted and Immunotherapies for Breast Cancer
This section covers the following topics:
Targeted therapies
Targeted therapies are designed to attack or kill cancer cells, while sparing normal cells as much as possible. These therapies are often designed to target abnormal proteins, receptors or genes that are found in high quantities in cancer cells or the surrounding tissue.
PARP inhibitors
PARP inhibitors are a type of that works by blocking a protein that the body uses to repair damage. They were initially developed to treat cancers in people with an inherited or mutation.
- For breast cancer, two PARP inhibitors have received FDA-approval as for treating people with an inherited mutation:
- Lynparza ()
- ()
- For people with early breast cancer at high risk for recurrence:
- Lynparza may be used as after chemotherapy in people with an inherited or mutation. Although the has not yet approved Lynparza for this indication, doctors may still prescribe it off-label. Several expert guidelines now include recommendations for Lynparza for patients with high-risk, early breast cancer and a or mutation.
Research is ongoing to learn if PARP inhibitors are affective for treating breast cancer in other situations, including:
- people with an in a different gene that repairs damage (for example: , or ).
- people who do not have an inherited gene mutation, but their tumor tested positive for an acquired mutation in a gene that repairs damage.
Other targeted therapies
Targeted therapies are treatments that act on certain molecules or targets within cancer cells to prevent the cancer cells from growing or spreading while sparing normal cells. Tumor testing can help doctors identify the patients most likely to benefit from a . Common targeted therapies used in breast cancer include:
- breast cancers are often treated with drugs that target the protein. Common anti-HER2 therapies include Herceptin (trastuzumab), Perjeta (pertuzumab) and Tukysa (tucatinib), Phesgo (pertuzumab, trastuzumab and hyaluronidase) and Enhertu (T-DXd).
- or advanced HER2-low breast cancers may be treated with the anti-HER2 drug Enhertu.
- People with advanced breast cancer are often treated with CDK4/6 inhibitors. CDK4/6 inhibitors target proteins found in some breast cancers called CDK inhibitors. The three CDK4/6 inhibitors approved for use in breast cancer are: Ibrance (palbociclib), Kisqali (ribociclib) and Verzenio (abemaciclib).
- The drug Piqray (alpelisib) is approved for people who have advanced, breast cancer who test positive for a tumor called PIK3CA. PIK3CA is an acquired gene mutation found in some ER-positive breast cancers.
- The drug Truqap (capivasertib) combined with fulvestrant is approved to treat , advanced or breast cancer with a mutation in , PIK3 or AKT1 genes which recurred or got worse after standard hormone therapy.
Immunotherapies
Immunotherapies are cancer treatments that help the body’s immune system detect and attack cancer cells. Immune checkpoint inhibitors are a type of used to treat several types of cancer, including breast cancer. Some cancer cells can switch off the immune system. Immune checkpoint inhibitors are drugs that prevent this from happening. This allows the immune system to find, unmask and destroy cancer cells. Immune checkpoint inhibitors are approved for treating breast cancer in the following situations:
- Keytruda (pembrolizumab) is approved in combination with chemotherapy for treatment of that is or locally recurrent and unresectable that tests positive for a called .
- Keytruda is approved for the treatment of triple-negative breast cancer that is at high risk for recurrence. In this setting, Keytruda is used along with chemotherapy as therapy before surgery. Following surgery, Keytruda is continued alone.
See our section for more information.
Table of targeted and immunotherapies for breast cancer
Name of drug | Cancer | Indication | Type of agent | |
---|---|---|---|---|
Herceptin (trastuzumab) |
Early | The treatment of breast cancer | overexpression () | Antibody targeting receptors |
Perjeta (pertuzumab) |
Locally advanced, inflammatory or early | Combined with Herceptin (trastuzumab) and docetaxel as treatment before surgery () | overexpression () | Antibody targeting receptors |
Phesgo (pertuzumab, trastuzumab combined injection) | Early |
Before surgery () for tumors larger than 2 cm or node-positive or after surgery ( treatment) for early breast cancer that has a high likelihood of coming back |
overexpression () | Antibody targeting receptors |
Keytruda (pembrolizumab) | Early TNBC at high risk for recurrence | Before surgery Keytruda is used along with chemotherapy as therapy. Following surgery, Keytruda is continued alone. | Triple-negative (, ) |
Immune checkpoint inhibitor |
Lynparza () | Early breast cancer at high risk for recurrence | Given for one year as after completion of or and local treatment (surgery and, or radiation). | or inherited mutation | |
Kadcyla (trastuzumab emtansine) |
Early | therapy for people with early breast cancer who still have disease after taxane and treatment with Herceptin | overexpression () | Antibody targeting receptors |
Enhertu (fam-trastuzumab-deruxtecan-nxki) |
Treatment for people who have received a prior anti-HER2 therapy for breast cancer or had their breast cancer come back during or within 6 months of completing treatment for their breast cancer |
overexpression () | Antibody-drug conjugate (chemotherapy attached to antibody to ) | |
Enhertu (fam-trastuzumab-deruxtecan-nxki) | Treatment for people with tumors that are HER2-low who received chemotherapy in the setting and whose cancer no longer responds to hormonal therapy | HER2-low | Antibody-drug conjugate (chemotherapy attached to antibody to ) | |
Kadcyla (trastuzumab emtansine) |
For patients who previously received Herceptin and chemotherapy, separately or in combination. Patients should have either received therapy for disease, or developed disease recurrence during or within six months of completing therapy | overexpression () | Antibody targeting receptors | |
Tukysa (tucatinib) | In combination with Herceptin (trastuzumab) to treat cancer which has progressed after at least one prior treatment with an anti-HER2 treatment in the setting | overexpression () | Kinase inhibitor | |
Trodelvy (sacituzumab govitecan-hziy) | For breast cancer that progressed, recurred or did not respond to at least two previous lines of treatment | Triple-negative (, ) | Antibody-drug conjugate (chemotherapy attached to antibody found in ) | |
Afinitor (everolimus) |
Combined with Aromasin (exemestane) for postmenopausal women with advanced breast cancer which progressed with Femara (letrozole) or Arimidex (anastrozole) | and HER2-negative |
MTOR inhibitor (type of kinase inhibitor) | |
Orserdu |
Used alone to treat men or postmenopausal women with , breast cancer with an ESR1 mutation, which progressed after at least one line of hormone therapy therapy |
, , ESR1 mutation | SERD (selective receptor degrader or downregulator) | |
Piqray (alpelisib) |
Combined with Faslodex (fulvestrant) as treatment in men or post-menopausal women who progressed on or after treatment with hormone therapy. | and and PIK3CA-positive |
Kinase inhibitor | |
Truqap (capivasertib) |
Combined with fulvestrant as treatment for , advanced or breast cancer which recurred or got worse after standard hormone therapy. | , PIK3 or AKT1 mutation | Akt kinase inhibitor | |
Verzenio (abemaciclib) | Used alone to treat men or women with breast cancer that has progressed after treatment with hormone therapy and chemotherapy in the setting. | and |
CDK4/6 inhibitor | |
Combined with Faslodex (fulvestrant) as treatment in women whose disease progressed following endocrine therapy. | and | CDK4/6 inhibitor | ||
Ibrance (palbociclib) |
Combined with an aromatase inhibitor as treatment of advanced cancer as initial hormone therapy in postmenopausal women or in men |
and | CDK4/6 inhibitor | |
Combined with Faslodex (fulvestrant) as treatment in postmenopausal women or in men whose disease progressed following endocrine therapy | and | CDK4/6 inhibitor | ||
Kisqali (ribociclib) |
Combined with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women as initial hormone based therapy | and | CDK4/6 inhibitor | |
Combined with Faslodex (fulvestrant) for the treatment of postmenopausal women, as initial hormone based therapy. | and | CDK4/6 inhibitor | ||
Lynparza () | For treatment of patients who have previously received chemotherapy, or hormone therapy for patients with hormone receptor ()-positive disease | or mutation and | ||
() |
For treatment of breast cancer | or mutation and | ||
Keytruda (pembrolizumab) | Combined with chemotherapy for treatment of locally recurrent unresectable or triple negative breast cancer | Triple-negative ( and ) PD-L1-positive |
Immune checkpoint inhibitor |
The following organizations offer peer support services for people with, or at high risk for breast cancer:
- FORCE peer support:
- Our Message Boards allow people to connect with others who share their situation. Once you register, you can post on the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- Our Peer Navigation Program will match you with a volunteer who shares your mutation and situation.
- Connect online with our Private Facebook Group.
- Join our virtual and in-person support meetings.
- Other organizations that offer breast cancer support:
The following are studies looking at new treatments for people with TNBC.
- NCT03606967: Testing the Addition of an Individual Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Triple Negative Breast Cancer. This study will look at how well the combination of chemotherapy, and when used with or without a vaccine made specifically for each patient.
- NCT04468061: Saci-IO TNBC: Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative TNBC. This early phase study is looking at how safe and effective Trodelvy with or without Pembrolizumab is in patients who have that has spread to other parts of the body.
- NCT04020575: Using a Type of Called CAR-T to Treat Triple-Negative Breast Cancer. This study will look at how safe and how well a type of treatment made from the patient's cancer works for treatment certain types of breast cancer.
- NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With IV or Unresectable, Recurrent (InCITe). This studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating TNBC that has recurred.
- NCT04837209. Radiation, and in Triple Negative Breast Cancer (NADiR). This research study is looking to see whether the combination of Dostarlimab and plus Radiation Therapy (RT) is safe and effective in participants with triple negative breast cancer.
- NCT05081492: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and (Pembrolizumab) for Triple-Negative Breast Cancer. This study is looking at the safety, side effects, and best dose of a drug called CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer. CF33-hNIS-antiPDL1 is a virus that is designed to attack and kill cancer cells.
A number of other clinical trials for treating patients with TNBC can be found here.